Objectif
In women estrogens and their cognate receptors regulate reproductive activities and exert protective functions in skeletal, cardiovascular and nervous systems. With the increased life expectancy women spend now more than one third of their life in menopause, a physiological state in which ovaries stop producing sexual hormones. To date risks and benefits of post-menopause hormone replacement therapy (HRT) are still unclear. Indeed, clinical results are in strong conflict with experimental results, the latter showing a clear protective effect of estrogens against bone, vessel, skin and brain malfunctions.
EWA will build on existing knowledge, reagents and infrastructures landmarks of European excellence in estrogen research to focus on:
a) generation of innovative cell and animal models for the identification of the safest compounds to be used in HRT;
b) ascertainment of the therapeutic efficacy and risks of known and novel molecules to be used for HRT;
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicinepathology
- medical and health sciencesbasic medicinephysiology
Appel à propositions
FP6-2004-LIFESCIHEALTH-5
Voir d’autres projets de cet appel